RU2004132198A - Терапевтическое применение селективных ингибиторов pde10 - Google Patents
Терапевтическое применение селективных ингибиторов pde10 Download PDFInfo
- Publication number
- RU2004132198A RU2004132198A RU2004132198/15A RU2004132198A RU2004132198A RU 2004132198 A RU2004132198 A RU 2004132198A RU 2004132198/15 A RU2004132198/15 A RU 2004132198/15A RU 2004132198 A RU2004132198 A RU 2004132198A RU 2004132198 A RU2004132198 A RU 2004132198A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- neurodegenerative
- selective
- spiky
- neurons
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Claims (9)
1. Способ определения наличия у химического соединения активности селективного ингибитора PDE10, включающий:
a) введение химического соединения в культуру медиальных шиповатых нейронов; и
b) измерение возможного повышения фосфорилирования CREB в культуре; повышение фосфорилирования CREB, тем самым показывает, что соединение, использованное в стадии (a) обладает селективной ингибиторной активностью в отношении PDE10.
2. Способ определения наличия у химического соединения активности селективного ингибитора PDE10, включающий:
a) введение химического соединения в культуру медиальных шиповатых нейронов; и
b) измерение возможного повышения количества продуцируемого GABA медиальными шиповатыми нейронами в указанной культуре;
повышение продукции GABA указанными медиальными шиповатыми нейронами, тем самым показывает, что соединение, использованное в стадии (a) обладает селективной ингибиторной активностью в отношении PDE10.
3. Способ лечения расстройства, выбранного из обсессивно/компульсивного расстройства, синдрома Туретта и других тиков у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для лечения указанного расстройства.
4. Способ лечения нейродегенеративного расстройства или состояния у млекопитающего, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для лечения указанного расстройства или состояния.
5. Способ по п. 4, где нейродегенеративное расстройство или состояние выбрано из болезни Паркинсона; болезни Гентингтона; деменции, например, деменции при болезни Альцгеймера, мультиинфарктной деменции, деменции при СПИДе; и фронто-темпоральной деменции; нейродегенеративного процесса, связанного с травмой головного мозга; нейродегенеративного процесса, связанного с инсультом, нейродегенеративного процесса, связанного с инфарктом мозга; нейродегенеративного процесса, вызванного гипогликемией; нейродегенеративного процесса, связанного с эпилептическими припадками; нейродегенеративного процесса, связанного с нейротоксическим отравлением; и множественной системной атрофии.
6. Способ по п. 4, где нейродегенеративное расстройство или состояние включает в себя нейродегенерацию медиальных шиповатых нейронов млекопитающих.
7. Способ по п. 5, где нейродегенеративным расстройством или состоянием является болезнь Гентингтона.
8. Способ лечения двигательного расстройства, выбранного из болезни Гентингтона и дискинезии, связанной с терапевтическим применением агонистов допамина, у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для ингибирования PDE10.
9. Способ лечения расстройства, выбранного из обсессивно/компульсивного расстройства, синдрома Туретта и других тиков у млекопитающих, включающий введение указанному млекопитающему количества селективного ингибитора PDE10, эффективного для ингибирования PDE10.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/139,183 US20030018047A1 (en) | 2001-04-20 | 2002-05-03 | Therapeutic use of selective PDE10 inhibitors |
US10/139,183 | 2002-05-03 | ||
US10/177,018 | 2002-06-20 | ||
US10/177,018 US20030032579A1 (en) | 2001-04-20 | 2002-06-20 | Therapeutic use of selective PDE10 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004132198A true RU2004132198A (ru) | 2005-04-20 |
RU2303259C2 RU2303259C2 (ru) | 2007-07-20 |
Family
ID=29406263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004132198/15A RU2303259C2 (ru) | 2002-05-03 | 2003-04-22 | Терапевтическое применение селективных ингибиторов pde10 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030032579A1 (ru) |
EP (1) | EP1504118A2 (ru) |
JP (1) | JP2005524402A (ru) |
KR (1) | KR20040106455A (ru) |
CN (1) | CN1668761A (ru) |
AU (1) | AU2003222395A1 (ru) |
BR (1) | BR0309746A (ru) |
CA (1) | CA2484600A1 (ru) |
HR (1) | HRP20041029A2 (ru) |
IL (1) | IL164778A0 (ru) |
MX (1) | MXPA04010777A (ru) |
NO (1) | NO20044470L (ru) |
PL (1) | PL373943A1 (ru) |
RU (1) | RU2303259C2 (ru) |
TW (1) | TWI269812B (ru) |
WO (1) | WO2003093499A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2657540C2 (ru) * | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005002579A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
WO2005003129A1 (en) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
EP1723134A2 (en) * | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
EP1755611A1 (en) * | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
AU2005323794B2 (en) * | 2005-01-07 | 2012-07-19 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
EP1838707B1 (en) * | 2005-01-12 | 2009-04-29 | Nycomed GmbH | Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
CA2650976A1 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
CA2661850A1 (en) * | 2006-09-01 | 2008-03-06 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
US20090318385A1 (en) * | 2006-09-06 | 2009-12-24 | Yasushi Kohno | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient |
US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
RU2449790C2 (ru) * | 2007-03-27 | 2012-05-10 | Омерос Корпорейшен | Использование ингибиторов pde7 для лечения нарушений движения |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
KR20100110804A (ko) * | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-a]피라진 |
EP2227472A1 (en) * | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
US8071595B2 (en) | 2008-06-25 | 2011-12-06 | Envivo Pharmaceuticals, Inc. | 1,2-disubstituted heterocyclic compounds |
WO2010006130A2 (en) | 2008-07-09 | 2010-01-14 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
EP2310016B1 (en) * | 2008-08-05 | 2017-10-04 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
WO2010035745A1 (ja) * | 2008-09-25 | 2010-04-01 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするpde阻害剤 |
TW201020233A (en) * | 2008-10-09 | 2010-06-01 | Kyorin Seiyaku Kk | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
SI2617420T1 (sl) | 2009-05-07 | 2016-02-29 | Forum Pharmaceuticals Inc. | Fenoksimetil heterociklične spojine |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
TW201111383A (en) | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
TW201102387A (en) * | 2009-06-08 | 2011-01-16 | Medicinova Inc | Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity |
TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
NZ705058A (en) * | 2010-03-12 | 2016-10-28 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
EP2675791B1 (en) | 2011-02-18 | 2016-02-17 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
EP2780324B1 (en) | 2011-11-09 | 2017-05-17 | Abbvie Deutschland GmbH & Co. KG | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
AR089361A1 (es) | 2011-12-21 | 2014-08-20 | Lundbeck & Co As H | Derivados de quinolina como inhibidores de la enzima pde10a |
US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
WO2014041175A1 (en) | 2012-09-17 | 2014-03-20 | Abbott Gmbh & Co. Kg | Novel inhibitor compounds of phosphodiesterase type 10a |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
HUE043059T2 (hu) | 2013-02-27 | 2019-07-29 | Mochida Pharm Co Ltd | Új pirazolszármazék |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
US9163019B2 (en) | 2013-03-14 | 2015-10-20 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
CA2980801A1 (en) | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
CN110346004B (zh) * | 2019-08-16 | 2020-08-21 | 杭州山科智能科技股份有限公司 | 一种双声道超声时差法的流量测量数据融合方法 |
AU2021285225A1 (en) * | 2020-06-05 | 2023-01-19 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of Tourette Syndrome |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
DE3224100A1 (de) * | 1982-06-29 | 1983-12-29 | Michael 6950 Schriesheim Long | Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen |
US5487976A (en) * | 1993-10-15 | 1996-01-30 | Cornell Research Foundation, Inc. | DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells |
US20040152106A1 (en) * | 1999-10-07 | 2004-08-05 | Robertson Harold A. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
DE60210014T2 (de) * | 2001-07-31 | 2006-09-21 | Pfizer Products Inc., Groton | Auf Zellen gegründetes Phosphodiesterase-10A-Assay und Sequenzen |
-
2002
- 2002-06-20 US US10/177,018 patent/US20030032579A1/en not_active Abandoned
-
2003
- 2003-04-22 RU RU2004132198/15A patent/RU2303259C2/ru not_active IP Right Cessation
- 2003-04-22 WO PCT/IB2003/001684 patent/WO2003093499A2/en not_active Application Discontinuation
- 2003-04-22 JP JP2004501635A patent/JP2005524402A/ja active Pending
- 2003-04-22 MX MXPA04010777A patent/MXPA04010777A/es unknown
- 2003-04-22 CN CNA038095335A patent/CN1668761A/zh active Pending
- 2003-04-22 AU AU2003222395A patent/AU2003222395A1/en not_active Abandoned
- 2003-04-22 BR BRPI0309746-3A patent/BR0309746A/pt not_active IP Right Cessation
- 2003-04-22 KR KR10-2004-7017684A patent/KR20040106455A/ko not_active Application Discontinuation
- 2003-04-22 CA CA002484600A patent/CA2484600A1/en not_active Abandoned
- 2003-04-22 EP EP03717481A patent/EP1504118A2/en not_active Withdrawn
- 2003-04-22 PL PL03373943A patent/PL373943A1/xx not_active Application Discontinuation
- 2003-04-28 TW TW092109924A patent/TWI269812B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/779,212 patent/US20040162294A1/en not_active Abandoned
- 2004-10-20 NO NO20044470A patent/NO20044470L/no not_active Application Discontinuation
- 2004-10-21 IL IL16477804A patent/IL164778A0/xx unknown
- 2004-11-02 HR HRP20041029 patent/HRP20041029A2/xx not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2657540C2 (ru) * | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
Also Published As
Publication number | Publication date |
---|---|
PL373943A1 (en) | 2005-09-19 |
TW200307751A (en) | 2003-12-16 |
EP1504118A2 (en) | 2005-02-09 |
NO20044470L (no) | 2004-11-04 |
BR0309746A (pt) | 2007-03-27 |
TWI269812B (en) | 2007-01-01 |
RU2303259C2 (ru) | 2007-07-20 |
US20040162294A1 (en) | 2004-08-19 |
KR20040106455A (ko) | 2004-12-17 |
AU2003222395A1 (en) | 2003-11-17 |
HRP20041029A2 (en) | 2004-12-31 |
US20030032579A1 (en) | 2003-02-13 |
IL164778A0 (en) | 2005-12-18 |
CN1668761A (zh) | 2005-09-14 |
MXPA04010777A (es) | 2005-03-07 |
WO2003093499A3 (en) | 2004-04-22 |
JP2005524402A (ja) | 2005-08-18 |
CA2484600A1 (en) | 2003-11-13 |
WO2003093499A2 (en) | 2003-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004132198A (ru) | Терапевтическое применение селективных ингибиторов pde10 | |
JP2005524402A5 (ru) | ||
Siwek et al. | Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer’s disease | |
Tamagno et al. | β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways | |
Disadee et al. | Chirality Transfer from Guanidinium Ylides to 3-Alkenyl (or 3-Alkynyl) Aziridine-2-carboxylates and Application to the Syntheses of (2 R, 3 S)-3-Hydroxyleucinate and d-e rythro-Sphingosine | |
WO2002053577A3 (en) | Gabaa modulating neurosteroids | |
TW200703444A (en) | Substrate processing apparatus, history information recording method, history information recording program, and history information recording system | |
FR2892409B1 (fr) | Procede de traitement d'un substrat | |
WO2007028149A3 (en) | Screening of inert solids from a low-yield wastewater treatment process | |
DE602006020327D1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen | |
MY137128A (en) | Hydrocyanation | |
EA200900258A1 (ru) | Ингибиторы растворимой эпоксидгидролазы, фармацевтическая композиция на их основе и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой | |
MXPA05010630A (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios. | |
EP1787972A3 (en) | Process for washing a distillation column used for the purification of (meth)acrylic acids | |
DK2005162T3 (da) | Screeningsmetode | |
ATE514724T1 (de) | Verfahren zur bildung gradient (meth)acrylathaltiger präpolymere | |
DE60309719D1 (de) | N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis | |
EP1571127A3 (en) | Production process for carbonized product and carbonized product obtained by the same process | |
WO2005016267A3 (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
FR2854244B1 (fr) | Procede de traitement, et notamment de filtrage, de donnees sismiques correspondant a des acquisitions realisees sur un milieu presentant une anisotropie azimutale | |
Qi et al. | Preventing expression of the nicotinic receptor subunit α7 in SH-SY5Y cells with interference RNA indicates that this receptor may protect against the neurotoxicity of Aβ | |
FR2886867B1 (fr) | Procede de fabrication d'un compose de type gel, pour le traitement d'effluent | |
FR2929876B1 (fr) | Procede de traitement d'un element en bois d'une espece particuliere. | |
ATE338050T1 (de) | Verfahren zur asymmetrischen hydrierung von ketocarbonsäureestern | |
DE60233279D1 (de) | Verfahren zum Herstellen von racemischem 3-hydroxy-3-(2-phenylethyl)-Hexansäureester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080423 |